West of Scotland Coronary Prevention Study

The West of Scotland Coronary Prevention Study, also known as WOSCOPS, was a randomized, double-blind, placebo-controlled clinical trial, published in 1995.[1] It compared 40mg of the lipid-lowering drug pravastatin to placebo in 6,595 men who had a mean cholesterol of 7 mmol/L but no previous history of a heart attack. The study concluded that statin treatment for primary prevention reduced coronary heart disease (CHD) events by 31% after nearly five years of treatment.[2][3][4]

## See also

* Heart Protection Study
* Scandinavian Simvastatin Survival Study

## References

1. ↑ Shepherd, James; Cobbe, Stuart M.; Ford, Ian; Isles, Christopher G.; Lorimer, A. Ross; Macfarlane, Peter W.; McKillop, James H.; Packard, Christopher J. (16 November 1995). "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia". New England Journal of Medicine 333 (20): 1301–1308. doi:10.1056/NEJM199511163332001. PMID 7566020.
2. ↑ Myat, Aung; Gershlick, A. H.; Gershlick, Tony (2012) (in en). Landmark Papers in Cardiovascular Medicine. Oxford University Press. pp. 32. ISBN 978-0-19-959476-4. https://books.google.com/books?id=DDmYywOVlToC&pg=PA32.
3. ↑ "The West of Scotland Coronary Prevention Study: Long-Term Results". http://www.medscape.com/viewarticle/565515.
4. ↑ Kashef, Mohammed Amin; Giugliano, Gregory (2017). "Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS)". Global Cardiology Science & Practice 2016 (4): e201635. doi:10.21542/gcsp.2016.35. ISSN 2305-7823. PMID 28979904.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/West of Scotland Coronary Prevention Study. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:West_of_Scotland_Coronary_Prevention_Study&oldid=395869"